SRX Global Says UC Davis Activated As Clinical Trial Site For CERTAIN-T, Ongoing Phase 1 Study Evaluating CER-1236 In Patients With Hematologic Malignancies Being Conducted By CERo Therapeutics

UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics

Update follows SRX’s previously announced definitive agreement to acquire CERo Therapeutics

NORTH PALM BEACH, Fla., Oct. 26, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE:SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value through investments in high-conviction operating companies and strategic assets, today announced that the University of California, Davis ("UC Davis") has been activated as a clinical trial site for CERTAIN-T, the ongoing Phase 1 study evaluating CER-1236 in patients with hematologic malignancies being conducted by CERo Therapeutics, the operating subsidiary of CERo Therapeutics Holdings, Inc. (OTCQB:CERO) ("CERo Holdings" and, together with CERo Therapeutics, "CERo"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms. UC Davis also serves as the primary manufacturing site for CER-1236.

The activation of UC Davis is expected to expand patient recruitment capacity while leveraging the site's existing manufacturing capabilities to streamline treatment logistics.